Filing Flows › Spero Therapeutics (SPRO) › Next earnings date
Spero Therapeutics (SPRO) earnings on Nov 12, 2026: what to expect
Spero Therapeutics (SPRO) is expected to report earnings on Nov 12, 2026 (estimated), in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.14 (1 estimate), against −$0.13 and $5.4M a year ago. It beat the EPS estimate in 100% of the quarters on record; Filing Flows' model gives it a 77% chance of beating next time.
What to watch
Last quarter (Q1 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.13 on revenue of $2.8M, against the analysts' −$0.14.
The last report
Spero Therapeutics reported revenue of $258K for the first quarter 2026 (-96% Y/Y), net loss $7.2M. How it makes money → · Every quarter →
Spero Therapeutics' latest quarter
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
Questions
When does SPRO report earnings?
Spero Therapeutics is expected to report on Nov 12, 2026 (estimated).
What are analysts expecting from Spero Therapeutics?
EPS of −$0.14 for the quarter.
Does Spero Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 100% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.